Medicxi Links With Sosei Heptares For Orexin Agonist Vehicles

After spending 12 months looking for promising orexin agonist candidates, asset-centric venture capitalist Medicxi finds answer close to home and commits up to €40M to create two companies underpinned by assets from Heptares Therapeutics.

Scientist

Underpinned by a strong background in the CNS space and experience with the orexin system, Medicxi, the European life sciences venture capitalist, is investing up to €40m in two asset-centric companies with assets spun out of Sosei Group's Heptares Therapeutics Ltd.. Both companies will focus on developing novel therapies based on positive modulators of the G protein-coupled receptors Orexin OX1 and OX2 for neurological diseases, including dual OX1/OX2 agonists. This is a group of molecules that has been on Medicxi’s wish list for some time.

“Orexin is one of the best validated targets and already a number of antagonists have been made. Minerva, one of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

More from Therapy Areas